Gonal-f RFF
Infertility Treatment May Raise Birth Defect Risk »
"Oct. 20, 2012 -- Babies conceived with the help of high-tech fertility treatments such as in vitro fertilization (IVF) have an increased risk for birth defects, a new study shows.
Compared to infants born to mothers who conceived with"...
Read the Infertility Treatment May Raise Birth Defect Risk article »
Gonal-f RFF
CLINICAL PHARMACOLOGY
Gonal-f® RFF (follitropin alfa for injection) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Gonal-f® RFF (follitropin alfa injection) is the primary hormone responsible for follicular recruitment and development. In order to effect final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following the administration of Gonal-f® RFF (follitropin alfa injection) when monitoring of the patient indicates that sufficient follicular development has occurred. There is interpatient variability in response to FSH administration.
Pharmacokinetics
Single-dose pharmacokinetics of follitropin alfa were determined following subcutaneous administration of 300 IU Gonal-f® RFF (follitropin alfa injection) to 21 pre-menopausal healthy female volunteers who were pituitary down-regulated with a GnRH agonist.
The descriptive statistics for the pharmacokinetic parameters are presented in Table 1.
Table 1: Pharmacokinetic parameters of FSH following administration of Gonal-f® RFF (follitropin alfa injection)
| Population Dose (IU) |
Healthy Volunteers (n=21) 300 IU SC in a single dose |
|
| Mean | %CV | |
| AUClast (IU•hr/L) | 884 | 20% |
| Cmax (IU/L) | 9.83 | 23% |
| tmax (hr) | 15.5 | 43% |
| t½ (hr) | 53 | 52% |
| Abbreviations are: Cmax: peak concentration (above baseline); tmax : time of Cmax; t½: elimination half life | ||
Absorption
The absorption rate of Gonal-f® RFF (follitropin alfa injection) following subcutaneous administration is slower than the elimination rate. Hence, the pharmacokinetics of Gonal-f® RFF (follitropin alfa injection) are absorption rate-limited.
Distribution
Human tissue or organ distribution of FSH has not been determined for Gonal-f® RFF (follitropin alfa injection) .
Metabolism/Excretion
FSH metabolism and excretion following administration of Gonal-f® RFF (follitropin alfa injection) have not been studied in humans.
Special populations
Safety, efficacy, and pharmacokinetics of Gonal-f® RFF (follitropin alfa injection) in patients with renal or hepatic insufficiency have not been established.
Drug-Drug Interactions
No drug-drug interaction studies have been conducted (see PRECAUTIONS).
Clinical Studies
The safety and efficacy of Gonal-f® RFF (follitropin alfa injection) have been examined in two clinical studies: one study (Study 22240) for ovulation induction and one study (Study 21884) for assisted reproductive technologies (ART).
Ovulation Induction (OI)
Study 22240 was a phase III, assessor-blind, randomized, comparative, multinational, multicenter study in oligo-anovulatory infertile women undergoing ovulation induction. Patients were randomized to either Gonal-f® RFF (follitropin alfa injection) (n=83), administered subcutaneously, or a comparator recombinant human FSH. The use of insulin-sensitizing agents was allowed during the study. Efficacy was assessed using the mean ovulation rate in the first cycle of treatment. The cycle 1 ovulation rate (primary outcome) for Gonal-f® RFF (follitropin alfa injection) is presented in Table 2. Additionally, this table includes cumulative secondary outcome results from cycle 1 through 3. Study 22240 was not powered to demonstrate differences in these secondary outcomes.
Table 2: Cumulative Ovulation and Clinical Pregnancy Rates in Ovulation Induction
| Study 22240 | Gonal-f® RFF (n=83) |
| Cumulativea Ovulation Rate | |
| Cycle 1 | 72%b |
| Cycle 2 | 89%d |
| Cycle 3 | 92%d |
| Cumulativea Clinical Pregnancyc Rate | |
| Cycle 1 | 28%d |
| Cycle 2 | 41%d |
| Cycle 3 | 45%d |
| a Cumulative rates were determined
per patient over cycles 1, 2, and 3. b Non-inferior to comparator recombinant human FSH based on a two-sided 95% confidence interval, intent-to-treat analysis. c A clinical pregnancy was defined as a pregnancy during which a fetal sac (with orwithout heart activity) was visualized by ultrasound on day 34-36 after hCG administration. d Secondary efficacy parameter. Study 22240 was not powered to demonstrate differences in this parameter. |
|
Assisted Reproductive Technologies (ART)
Study 21884 was a phase III, assessor-blind, randomized, comparative, multinational, multicenter study in ovulatory, infertile women undergoing stimulation of multiple follicles for Assisted Reproductive Technologies (ART) after pituitary down-regulation with a GnRH agonist. Patients were randomized to either Gonal-f® RFF (follitropin alfa injection) (n=237), administered subcutaneously, or a comparator recombinant human FSH. Randomization was stratified by insemination technique [conventional in-vitro fertilization (IVF) vs. intra-cytoplasmic sperm injection (ICSI)]. Efficacy was assessed using the mean number of fertilized oocytes the day after insemination. The initial doses of Gonal-f® RFF (follitropin alfa injection) were 150 IU a day for patients < 35 years old and 225 IU for patients ≥ 35 years old. The maximal dose allowed for both age groups was 450 IU per day. Treatment outcomes for Gonal-f® RFF (follitropin alfa injection) are summarized in Table 3.
Table 3: Treatment Outcomes in ART
| Study 21884 | Gonal-f® RFF value (n) |
| Mean number of 2PN oocytes per patient | 6.3 (237)a |
| Mean number of 2PN oocytes per patient receiving IVF | 6.1 (88)b |
| Mean number of 2PN oocytes per patient receiving ICSI | 6.5 (132)b |
| Clinical pregnancyc rate per attempt | 33.5% (218)d |
| Clinical pregnancyc rate per embryo transfer | 35.8% (204)d |
| Mean treatment duration in days (range) | 9.7 [3-21] (230)d |
| a Non-inferior to comparator recombinant human
FSH based on a two-sided 95% confidence interval, intent-to-treat analysis b Study 21884 was not powered to demonstrate differences in subgroups c A clinical pregnancy was defined as a pregnancy during which a fetal sac (with or without heart activity) was visualized by ultrasound on day 35-42 after hCG administration. d Secondary efficacy parameter. Study 21884 was not powered to demonstrate differences in this parameter |
|
Last reviewed on RxList: 7/26/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Gonal-f RFF Information
Gonal-F - User Reviews
Gonal-F User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Gonal-F sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Trying to Conceive
Get tips and advances in treatment.
Updated & New
